The Symplicity Spyral™ renal denervation (RDN) system is a minimally invasive treatment for hypertension. It is the first catheter-based radiofrequency treatment designed to complement medications and lifestyle modifications for patients with uncontrolled high blood pressure.

Backed by more than 15 years of research and clinical evidence, this procedure has demonstrated significant and sustained blood pressure reductions with a strong safety profile. With Medicare coverage established and thousands of patients treated worldwide, Symplicity is improving access to care, expanding treatment options, and delivering meaningful outcomes for patients with uncontrolled hypertension.

Congratulations to Medtronic, the winner of the TAG Award for B2B Innovation Medical Technology: Cardiovascular Treatment & Therapeutic Innovation.